| Website | gentisinc.com |
| Category | BioTech |
| Phone | 610-971-0990 |
| info@gentisinc.com | |
| Employees |
| TOTAL | $10M |
| FUNDING TOTAL | $10M |
| Series A, 6/07 Pappas Ventures Easton Capital Ivy Capital Matignon Investissement & Gestion | $10M |
Gentis is a developer of minimally invasive, biomaterials-based products intended to treat the early-stage degeneration of the spine. The company’s first patented product, DiscCell, is an injectable, in-situ setting, radio-opaque, non-hydrogel polymer material that augments or replaces the diseased nucleus pulposus of the spinal disc.
